NDRA
ENDRA Life Sciences Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$6.05
+6.51%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 39.7K | — | — | — | — |
| Gross Profit | (39.7K) | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 2.0M | 1.8M | 3.2M | 5.0M | 6.6M |
| SG&A Expense | 4.7M | 3.9M | 7.6M | 5.5M | 6.6M |
| General & Admin Expense | 4.6M | 3.7M | 7.1M | 4.7M | 5.2M |
| Selling & Marketing Expense | 61.7K | 189.5K | 571.0K | 820.6K | 1.4M |
| Other Expenses | (39.7K) | — | — | — | — |
| Total Operating Expenses | 6.6M | 5.8M | 10.8M | 10.5M | 13.2M |
| Cost and Expenses | 6.6M | 5.8M | 10.8M | 10.5M | 13.2M |
| Operating Income (EBIT) | (6.6M) | (5.8M) | (10.8M) | (10.5M) | (13.2M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | 21.5K |
| Net Interest Income | — | — | — | — | (21.5K) |
| Other Non-Op Income/Expense | 733.1K | (1.3M) | (690.8K) | 460.5K | (21.5K) |
| Non-Operating Income (excl Interest) | 910.1K | 1.3M | 690.8K | (460.5K) | — |
| EBT (Pre-Tax Income) | (5.9M) | (7.0M) | (11.5M) | (10.1M) | (13.2M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (5.9M) | (7.0M) | (11.5M) | (10.1M) | (13.2M) |
| Earnings from Cont. Ops | (5.9M) | (7.0M) | (11.5M) | (10.1M) | (13.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (5.9M) | (7.0M) | (11.5M) | (10.1M) | (13.2M) |
| Per Share | |||||
| Basic EPS | ($6.33) | ($8.93) | ($10.25) | ($5.89) | ($4.57) |
| Diluted EPS | ($6.39) | ($8.93) | ($10.25) | ($5.89) | ($6.84) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 1.3M | 787020 | 1.1M | 1.7M | 1.9M |
| Diluted Shares Outstanding | 2.5M | 787020 | 1.1M | 1.7M | 1.9M |
| Profitability Metrics | |||||
| EBITDA | (7.4M) | (6.9M) | (11.3M) | (9.8M) | (12.9M) |
| D&A | 126.8K | 157.3K | 206.2K | 275.5K | 234.3K |
| EBIT | (7.6M) | (7.0M) | (11.5M) | (10.1M) | (13.2M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026